Unipolar Radiofrequency Device Safe, Effective for Face Tightening

This article originally appeared here.
Share this content:
Unipolar Radiofrequency Device Safe, Effective for Face Tightening
Unipolar Radiofrequency Device Safe, Effective for Face Tightening

FRIDAY, Feb. 17, 2017 (HealthDay News) -- For subjects with facial laxity, a novel fractional unipolar radiofrequency (RF) device is safe and efficacious for facial tightening, according to a study published online Feb. 13 in the Journal of Cosmetic Dermatology.

Dong Hye Suh, M.D., from Arumdaun Nara Dermatologic Clinic in Seoul, South Korea, and colleagues examined the safety and efficacy of a novel fractional unipolar RF device on facial tightening in a retrospective study involving 14 individuals with age-related facial laxity (mean age, 49.7 years). Participants underwent five sessions of fractional unipolar RF at an interval of two weeks and were followed for three months. Two independent dermatologists assessed standardized photographs taken at baseline and at three-month follow-up.

The researchers found that in follow-up photographs, 35.7, 50, and 14.3 percent of subjects had significant, moderate, and slight improvement of facial laxity. At three-month follow-up, about 85.7 percent of the subjects reported being greatly satisfied or satisfied with the results. An increase in collagen in the dermis was seen in punch skin biopsies. There were no serious adverse events during or after the procedure.

"Our findings suggest that fractional unipolar RF can be safely performed on the face and is effective in skin tightening," the authors write. "It has a great advantage over other forms of RF by being entirely painless."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »